

Regulatory Story

[Go to market news section](#)



Intl. Biotechnology Trust PLC - IBT
Portfolio Update
Released 11:03 16-Aug-2018

RNS Number : 0339Y
Intl. Biotechnology Trust PLC
16 August 2018

INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)

Portfolio Update as at 31 July 2018

Net Assets	£251m
Net Assets per share	670p
Share price	668p
Total value of unquoted investments	£28m
Total number of portfolio companies	74
Dividend	4% of NAV per annum

Top Ten Quoted Investments

Company Name	% NAV
Celgene	6.9
Illumina	5.1
Vertex	4.4
Genmab	3.9
Exelixis	3.7
Regeneron	3.5
Morphosys	3.4
Alexion	3.3
Neurocrine	3.3
Array	3.2

	-
Total	40.7

Geographical Allocation	% NAV
US & Canada	86

Europe	14

	-
Total	100

Quoted/Unquoted Allocation	% NAV
Quoted	89
Unquoted	11

	-
Total	100

NAV % Market Cap	% NAV
Large Cap >USD10BN	35
Mid Cap =USD1-10BN	41
Small Cap <USD1BN	24

	-
Total	100

NAV % by Therapeutic Areas	% NAV
Oncology	47
CNS	13
Rare diseases	14
Ophthalmology	7
Infectious Diseases	3
Inflammation	2
Metabolic	2
Medtech	2
Other	10

	-
Total	100

BNP Paribas Secretarial Services Limited
Company Secretary

16 AUGUST 2018

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END